Literature DB >> 16965791

Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.

Milka Kostic1, Theresia Matt, Maria A Martinez-Yamout, H Jane Dyson, Peter E Wright.   

Abstract

Regulation of the transcriptional response to the tumor suppressor p53 occurs at many levels, including control of its transcriptional activity, and of its stability and concentration within the cell. p53 stability is regulated by the protein Hdm2, an E3 ubiquitin ligase that binds to p53 and promotes its ubiquitination and degradation. The C-terminal domain of Hdm2, which is critical for this activity, has been classified as a RING domain on the basis of sequence homology, although it lacks the canonical set of zinc ligands (RING domains typically have C3HC4 or C4C4 zinc coordination). Here, we report the solution structure of the C2H2C4 RING domain of Hdm2(429-491), which reveals a symmetrical dimer with a unique cross-brace zinc-binding scheme. Each subunit has one Cys4 Zn site and one His2Cys2 Zn site. The global fold of each subunit is similar to those reported for other RING domains, with a compact betabetaalphabeta fold, a small hydrophobic core, and two Zn ions, which are essential for maintaining the domain structure. The dimer structure is maintained by an extensive interface that buries a large hydrophobic area on each subunit. It has been proposed that Hdm2 and its homologue HdmX form a stable heterodimer through their RING domains, resulting in a synergistic increase in observed E3 activity. To test this proposal, we prepared an HdmX RING construct and showed by NMR titration that it forms a tight 1:1 complex with the Hdm2 RING. The resonances most perturbed by heterodimer formation are located within the subunit interface of the homodimer, far removed from the surface expected to form the docking site of the E2 ubiquitin-conjugating enzyme, providing a structure-based rationale for the function of the RING domains in p53 ubiquitination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965791     DOI: 10.1016/j.jmb.2006.08.027

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  60 in total

1.  Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers.

Authors:  Pavlina Dolezelova; Katerina Cetkovska; Karen H Vousden; Stjepan Uldrijan
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

2.  Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage.

Authors:  Qian Cheng; Brittany Cross; Baozong Li; Lihong Chen; Zhenyu Li; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

3.  Turning the RING domain protein MdmX into an active ubiquitin-protein ligase.

Authors:  Saravanakumar Iyappan; Hans-Peter Wollscheid; Alejandro Rojas-Fernandez; Andreas Marquardt; Hao-Cheng Tang; Rajesh K Singh; Martin Scheffner
Journal:  J Biol Chem       Date:  2010-08-12       Impact factor: 5.157

4.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

Review 5.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

6.  The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.

Authors:  Masha V Poyurovsky; Christina Priest; Alex Kentsis; Katherine L B Borden; Zhen-Qiang Pan; Nikola Pavletich; Carol Prives
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

7.  beta-arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53.

Authors:  Cédric Boularan; Mark G H Scott; Karima Bourougaa; Myriam Bellal; Emmanuel Esteve; Alain Thuret; Alexandre Benmerah; Marc Tramier; Maité Coppey-Moisan; Catherine Labbé-Jullié; Robin Fåhraeus; Stefano Marullo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

Review 8.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 9.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

10.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.